Evaluation of EGFR and K-ras Mutations in Patients With Stage III NSCLC Treated on CALGB 30106
- Determine the frequency of epidermal growth factor receptor (EGFR) and K-ras mutations
in patients with stage III non-small cell lung cancer (NSCLC) treated on CALGB 30106.
- Correlate presence or absence of EGFR and/or K-ras mutations with radiographic response
to treatment in these patients.
OUTLINE: Tissue samples are analyzed for epidermal growth factor receptor and K-ras
PROJECTED ACCRUAL: A total of 49 patient specimens will be accrued for this study.
Frequency of epidermal growth factor receptor (EGFR) and K-ras mutations
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
United States: Federal Government